Get started

Aldeyra Therapeutics, Inc

At close
No trades
See on super-charts
Overview
News Ideas Financials Technicals Forecast

ALDX chart

Key stats

Market capitalization
528.944MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.06USD

About Aldeyra Therapeutics, Inc

ISIN
US01438T1060
Sector
Health Technology
Industry
Biotechnology
Website
aldeyra.com
CEO
Todd C. Brady
Headquarters
Lexington
Employees
15
Founded
2004

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Ideas

Aldeyra Therapeutics Announces Positive Top-Line Data from PhaseALDX: Aldeyra Therapeutics, Inc. 2022-01-11 08:00:00 Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
Long
ALDX Announces Positive Top-Line Symptom and Sign ResultsAldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease Statistical Significance of Reproxalap Over Vehicle Achieved for Ocular Redness, an FDA-Approvable Sign, and Clinical Symptoms of Ocular Dryness and Discomfor
consolidation fazetoo much consolidation in this chart for a entry, no real trend or signs of a big breakout coming anytime soon. has been 5 years of sideways action and theres nothing stopping it from doing another 5! be careful if theirs calls on it ! very risky here imo, gl <3
2
aldxHere is a method I have learnt of that makes a ton of sense. Most use a a percentage of their portfolio money per trade to manage risk. This way here makes trades consistent and takes the 'too much/too little' effect out of the picture. Set an amount of money that you are willing to lose on each tra
2
$ALDX Phase 2 results on May 1st stock could soar.Sentiment has been very positive in ALDEYRA THERAPEUTICS having already released positive results for other pipeline drugs. On may 1st phase 2 results for its new Dry Eye Syndrome drug will be presented and optimism is high on the rumor mill. The current price target by 7 analysts covering the name
Long

See all ideas 

News flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
‪0‬
Revenue
‪0‬

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more